[
  {
    "ts": null,
    "headline": "FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria",
    "summary": "The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.",
    "url": "https://finnhub.io/api/news?id=af5ff7d9becb927e0a2cd500965c57dcbf904c41a25b13772838a5f7fe0f0182",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731960000,
      "headline": "FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria",
      "id": 131461790,
      "image": "https://media.zenfs.com/en/zacks.com/00ec4a55c0f0d99f7e816f5da7894e0c",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.",
      "url": "https://finnhub.io/api/news?id=af5ff7d9becb927e0a2cd500965c57dcbf904c41a25b13772838a5f7fe0f0182"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=413c724878e7eb4c5ec48bb1595475296b5d4d9bfffd701eeade04bb7931aaeb",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731948300,
      "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "id": 131477600,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=413c724878e7eb4c5ec48bb1595475296b5d4d9bfffd701eeade04bb7931aaeb"
    }
  },
  {
    "ts": null,
    "headline": "Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients",
    "summary": "Adverum Biotechnologies advances wet AMD treatment with promising trial results. See why ADVM stock has potential as it prepares for the ARTEMIS study in 2025.",
    "url": "https://finnhub.io/api/news?id=c449d2c711b077dad1110e90947c3179c50be8d13e52b3b16dc479d4fec8d830",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731937075,
      "headline": "Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients",
      "id": 131456312,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1302270618/image_1302270618.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Adverum Biotechnologies advances wet AMD treatment with promising trial results. See why ADVM stock has potential as it prepares for the ARTEMIS study in 2025.",
      "url": "https://finnhub.io/api/news?id=c449d2c711b077dad1110e90947c3179c50be8d13e52b3b16dc479d4fec8d830"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals, Inc. - Dupixent sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria",
    "summary": "TARRYTOWN, PARIS - Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration has accepted for review the resubmission of the supplemental Biologics...",
    "url": "https://finnhub.io/api/news?id=60fc542b7129b4d4d8f11228b72060f06ae710aed5c5a2ac88ac0034ca635ad9",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731913525,
      "headline": "Regeneron Pharmaceuticals, Inc. - Dupixent sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria",
      "id": 131440008,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "TARRYTOWN, PARIS - Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration has accepted for review the resubmission of the supplemental Biologics...",
      "url": "https://finnhub.io/api/news?id=60fc542b7129b4d4d8f11228b72060f06ae710aed5c5a2ac88ac0034ca635ad9"
    }
  }
]